Record order book & strong growth, but sequential momentum halts

₹2,598 Cr order book, ₹25.989 billion confirmed

1.5x book-to-bill confirmed; order intake ₹551.9 Cr

10.5% in Q1 FY27 (147 bps expansion YoY), confirmed 4-quarter run

34.3% YoY, but QoQ only +1.3% despite record order book

2 logos added across industrial/automotive, 30% of Q1 intake from new customers (4-6 quarter vintage)

Sales directors just onboarded Q1, no Q1 revenue yet, timeline TBD in next 2-3 quarters

PAT margin 4.4%, but QoQ PAT -27.4% despite revenue +1.3%

₹2,598 Cr vs ₹2,130 Cr in Q4 FY26 (₹183 Cr QoQ increase). Book-to-bill 1.5x vs 1.4x expected, reinforcing demand confidence.

Q1 PAT ₹163M (-27.4% QoQ from ~₹225M in Q4). Gross margin compression and organizational investment costs drove decline despite revenue growth.

16% of revenue, flat YoY growth vs prior quarters' expansion. Seasonal customer impact cited, but no visibility to recovery.

Chief Strategy & Growth Officer (Rama Alapati) onboarded; AI/robotics sales directors added. Enhances go-to-market for new segments (FY27-29 expand phase).

1.75-2x revenue run-rate; no incremental capex needed for AI/robotics expansion. Existing facilities sufficient for execution.

Crisis still present with logistics delays and cost increases observed. Strategic inventory build and execution planning mitigated Q1 impact. Israeli customer momentum continues; expect momentum in Q2. No material disruption seen yet.

Early stage. Sales directors onboarded this quarter. Will provide updates in next 1-2 quarters on focus areas and momentum. No concrete customer or timeline disclosed yet.

Expected 6-12 months for revenue growth impact. Existing capital equipment customers showing robust growth. Continued investment in this area.

No specific revenue guidance given. Internal plans exist for expand phase mix and CAGR, but not disclosed publicly. Updates once new customers secured (2-3 quarters).

Meaningful revenue in next 1-18 months. B2S will add 250-300 bps EBITDA margin upside to consolidated profile vs core EMS business.

Driven by higher inventory and lower customer advances to support growth. Justified as leading indicator for future revenue. Will normalize once growth rate moderates and inventory controlled.

No lumpy orders; 70% from existing customers, 30% from new logos onboarded last 4-6 quarters. Substantial opportunity still with both cohorts. 1.5x book-to-bill to be maintained for full year.

Honeywell: Major order won years back now entering initial production ramp. Expect significant growth coming 18 months. Strong engagement at multiple levels. Thales: Extraordinary growth expected this year. Multiple major OEM/Tier-1 accounts active.

Current expansion from filling hopper and operating leverage. Future upside from new sectors (AI, robotics, semicon capital equipment) to come in FY27-29, targeting 11-13% EBITDA. No inherent cost advantage; high-profile margin business model.

Rupee appreciated in Q1 final month; balance sheet exposed to export/import FX. Net impact visible on balance sheet. Standard exposure management.

Management expects order intake/momentum to continue at similar levels. 1.5x book-to-bill to be maintained for full year. No absolute revenue target or CAGR disclosed.

Four consecutive quarters of double-digit run achieved. Management committed to margin expansion via operating leverage and new-segment contribution (FY27-29 target: 11-13%).

Aspirational roadmap lacking quantified revenue ramp or concrete mechanisms. Timeline for meaningful new-segment revenue 2-3 quarters out.

Multi-year aspiration hinging on B2S product scaling and platform IP ownership. No P&L evidence yet; B2S meaningful revenue 1-18 months away.

Existing facilities and capabilities sufficient for AI/robotics/semicon expansion. Regular annual capex continues; no transformative investment needed.

AI data center and robotics positioned as 11-13% margin drivers by FY29, but only sales directors onboarded Q1. No Q1 revenue, customer proof, or product clarity. 2-3 quarter visibility lag critical risk to margin roadmap.

Inventory days 162 (up 9 QoQ); customer advances 15 days (down 3 QoQ); net WC days 161 (up 16 QoQ). Operating cash flow negative. Management justified as growth investment but tail risk if revenue conversion slows.

MedTech 16% of Q1 revenue, flat YoY, attributed to seasonal customer impact. No acceleration visible despite overall order book momentum. If sector slowdown persists, diversification thesis weakens and margin expansion dependent on aerospace/industrial leverage.

Q1 PAT ₹163M fell sharply QoQ (from ~₹225M Q4) as gross margin compressed due to organizational investments and procurement for B2S. Risk that margin expansion stalls if sequential execution doesn't improve.

West Asia crisis still ongoing; logistics delays and cost increases observed in Q1. Strategic inventory buildup and alternative sourcing mitigated impact in Q1, but sustainability risk if crisis persists or escalates. Israeli orders still in motion but with approvals delays.